List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 410 studies with search of: "Erlotinib"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Not yet recruiting Erlotinib and Temsirolimus for Solid Tumors
Condition: Solid Tumors
Interventions: Drug: erlotinib and temsirolimus;   Drug: erlotinib and temsirolimus;   Drug: erlotinib and temsirolimus;   Drug: erlotinib and temsirolimus;   Drug: erlotinib and temsirolimus;   Drug: erlotinib and temsirolimus
2 Not yet recruiting 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib plus docetaxel or pemetrexed;   Drug: erlotinib
3 Recruiting Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family
Conditions: Head and Neck Cancer;   Non Small Cell Lung Cancer
Interventions: Drug: Erlotinib;   Drug: Dasatinib plus Placebo;   Drug: Erlotinib plus Dasatinib;   Drug: Placebo;   Drug: Erlotinib
4 Active, not recruiting Erlotinib (Tarceva) vs. Standard Chemotherapy (Paclitaxel and Carboplatin) in Patients With Advanced NSCLC and ECOG PS 2
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Tarceva (Trademark) (erlotinib HCl, OSI-774);   Drug: Combination carboplatin and paclitaxel
5 Recruiting TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer
Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib;   Drug: cisplatin;   Drug: gemcitabine;   Drug: cisplatin;   Drug: gemcitabine;   Drug: erlotinib
6 Recruiting Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-3512676 + Erlotinib;   Drug: Erlotinib
7 Recruiting TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Conditions: Non-Small Cell Lung Cancer;   Lung Cancer
Interventions: Drug: Erlotinib;   Drug: Carboplatin;   Drug: Paclitaxel
8 Recruiting Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
Condition: Advanced Malignant Solid Tumors
Interventions: Drug: PM02734 and erlotinib;   Drug: Erlotinib
9 Active, not recruiting Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
Conditions: Advanced Non Small Cell Lung Cancer;   Failed Prior Chemotherapy
Intervention: Drug: Tarceva (Trademark) (erlotinib HCl, OSI-774)
10 Active, not recruiting Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib + Sorafenib;   Drug: Erlotinib + Placebo
11 Recruiting Phase I Imaging Study Evaluating MK0646 in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: Comparator: erlotinib + MK0646;   Drug: Comparator: erlotinib monotherapy
12 Recruiting MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Adenocarcinoma
Interventions: Drug: MK-0646;   Drug: Gemcitabine;   Drug: Erlotinib
13 Recruiting A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib;   Drug: sunitinib;   Drug: erlotinib;   Drug: placebo
14 Recruiting Ph I Dasatinib + Erlotinib in Recurrent MG
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Erlotinib and Dasatinib
15 Recruiting BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC
Condition: Lung Cancer
Intervention: Drug: Erlotinib
16 Active, not recruiting Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Erlotinib, Sirolimus
17 Recruiting A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: erlotinib;   Drug: sunitinib;   Drug: erlotinib;   Drug: placebo
18 Recruiting Erlotinib in Combination With Cetuximab
Condition: Advanced Cancers
Interventions: Drug: Erlotinib;   Drug: Cetuximab
19 Active, not recruiting Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Erlotinib;   Drug: Bevacizumab
20 Recruiting Neoadjuvant Erlotinib (Tarceva) in Transitional Cell Carcinoma
Condition: Transitional Cell Carcinoma
Intervention: Drug: Erlotinib Hydrochloride

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services